...By Sandi Wong, Assistant Editor Regeneron reported Phase...
...to more severe disease. In the trial, which Regeneron Pharmaceuticals Inc....
...BNT162, BNT162b2) COVID-19 Vaccine Janssen (Ad26.COV2.S, JNJ-78436735) mavrilimumab (cam-3001) AKL-T01, SDT-001 Regeneron Pharmaceuticals Inc. Pfizer...

...indication versus three other Phase III programs as well as marketed drug Dupixent dupilumab from Regeneron Pharmaceuticals Inc....

...Corp. (NASDAQ:UTHR) and Sanofi (Euronext:SAN; NASDAQ:SNY) and expanded the labels of PCSK9 inhibitor Praluent alirocumab from Regeneron Pharmaceuticals Inc....
...Compound #), REGN727 (Compound #), alirocumab (Generic), Praluent (Other) Coalition for Epidemic Preparedness Innovations (CEPI) BioNTech SE Pfizer Inc. Regeneron Pharmaceuticals Inc. United...

...which Lilly developed with Shanghai Junshi Biosciences Co. Ltd. (HKEX:1877; Shanghai:688180); and the two-mAb cocktail REGEN-COV-2 from Regeneron Pharmaceuticals Inc....

...the biotech’s COVID mAb pipeline than they have on Lilly’s products. An authorized mAb cocktail from Regeneron Pharmaceuticals Inc....
...compete with vaccines. Lilly and Regeneron are both testing subcutaneous versions of their drugs. In January, Regeneron...
...COMET-TAIL, in high-risk patients; and COMET-STAR, in uninfected individuals as prophylaxis. In addition to Lilly and Regeneron’s...

...China, Mexico and Pakistan.Phase III readout for Regeneron...
...Ad5-nCoV) casirivimab/imdevimab (REGEN-COV, REGN-COV2, REGN-COVID19, REGN10933/REGN10987) CureVac N.V. CanSino Biologics Inc. Regeneron Pharmaceuticals Inc. AstraZeneca...

...Lilly and the REGEN-COV (casirivimab/imdevimab) cocktail from Regeneron Pharmaceuticals Inc....
...and authorized mAb cocktails from Lilly and Regeneron...
...first identified in South Africa. Products from Regeneron...

...Former compound #), AG-014699 (Former compound #), rucaparib (Generic) Keytruda, pembrolizumab (MK-3475, lambrolizumab) mavacamten (SAR439152, myk-461) Arcalyst, Rilonacept Regeneron...

...U.S.: the bamlanivimab/etesevimab combination from Eli Lilly and Co. (NYSE:LLY) and the casirivimab/imdevimab cocktail from Regeneron Pharmaceuticals Inc....
...mAbs from Lilly and its partners would be most likely to lose efficacy, while products from Regeneron...
...to 1 million doses of etesevimab for administration with bamlanivimab by mid-2021. Steve Usdin Eli Lilly and Co. Regeneron Pharmaceuticals Inc. covid-19 cov19count ASPR cov19count...

...in efficacy in the indication versus three other Phase III programs and Dupixent dupilumab from Regeneron Pharmaceuticals Inc....